We previously developed an ELISA assay for detection of tetanus toxoid antigen in tetanus vaccines for human use. Tetanus vaccines for veterinary use are qualitatively different to those used in humans, often containing a larger number and variety of non-tetanus antigens in the multi-valent products, and adjuvants that are not found in human vaccines. We assessed performance of the capture ELISA with a range of veterinary tetanus vaccines as a first step towards development of an immunoassay as a potential in vivo potency substitute. Nine tetanus vaccines were tested and all produced a good dose response in the ELISA. The shape of the dose response curve for the whole vaccine compared to a matched non-adjuvanted tetanus toxoid antigen was more comparable for vaccines containing a non-aluminium adjuvant than products containing aluminium adjuvants. Elution of the antigen from aluminium adjuvant did not improve the comparability of the dose response curve but did increase the total amount of tetanus antigen available for detection. The ELISA was highly specific for tetanus with no signal obtained for a large number of non-tetanus antigens. These results suggest that a capture ELISA assay can be applied to a control strategy for veterinary tetanus vaccines.
Introduction
The VAC2VAC project is public-private consortium of 22 partners funded by the Innovative Medicines Initiative 2 (IMI2). The main objective for the project is the development of in vitro assays that will support regulatory acceptance of a consistency approach [1] for established vaccines where potency and/or safety testing in animals is currently required, ultimately reducing the use of animals for batch testing as part of routine vaccine production in the future. More information on the VAC2VAC project can be found on the project website [2] . One of the specific aims is to develop an immunoassay(s) for tetanus vaccines that could be used as part of this approach to reduce the reliance on animal use for potency testing. Tetanus vaccine was selected as one of the target antigens since it is manufactured and used widely for the immunisation of both humans and animals. The potency of each batch of tetanus vaccine is determined for each final lot (or final formulated bulk) as part of routine lot release procedures. Although the test methodology varies in different regulatory jurisdictions all potency tests for tetanus vaccine currently require the use of animals [3, 4] .
Tetanus vaccines are produced by chemical detoxification of tetanus toxin to produce tetanus toxoid (TTxd) which is used alone or in combination with other antigens. Tetanus vaccine for human use, in combination vaccines containing other antigens, forms part of the routine immunisation schedule for infants in many countries [5] . All tetanus vaccines for human use contain an aluminium adjuvant (aluminium hydroxide, aluminium phosphate or a combination of both) and include additional non-tetanus components such as diphtheria toxoid, pertussis (acellular antigens or whole cell), inactivated poliomyelitis, hepatitis B surface antigen and Haemophilus influenza type b polysaccharide. We have previously developed an ELISA method for detection and quantification of tetanus antigen in tetanus vaccines and showed that this method could be applied to a range of different tetanus vaccines licensed for use in humans [6] . This work was a precursor to the further development and validation of ELISA-based approaches for the quality control of tetanus vaccines that is now being explored by the VAC2VAC consortium.
Tetanus is a disease that also affects animals, particularly grazing animals such as cattle and sheep, and horses which are among the most highly susceptible domestic species [7, 8] . Tetanus vaccines are widely used in these and other animal species. However, tetanus vaccines for veterinary use have significant qualitative differences to those used for immunisation of humans. Although the preparation of the tetanus antigen follows a similar process [9] , the final product in many cases contains multiple additional antigens and adjuvant types that are not found in vaccines licensed for human use. It was therefore necessary to https://doi.org/10.1016/j.biologicals.2019.08.003 Received 10 June 2019; Received in revised form 6 August 2019; Accepted 9 August 2019 explore to what extent an immunoassay approach previously applied to tetanus vaccine for human use might also be suitable for use with veterinary tetanus vaccines. We used a capture ELISA method which utilises a monoclonal antibody to capture the tetanus antigen and a polyclonal antibody for detection [6] and tested a number of tetanus vaccine products and production intermediates from four different veterinary tetanus vaccine manufacturers that are part of the VAC2VAC consortium. We measured tetanus antigen content in the production intermediates (drug substance) and final lot in the presence of adjuvant (drug product). For vaccines containing an aluminium-based adjuvant we also measured tetanus antigen content after desorption. Finally, we tested a range of non-tetanus antigens, including other clostridial antigens that are present in multicomponent vaccines that also contain TTxd, to determine specificity of the capture ELISA.
Materials and methods

Tetanus vaccine samples used in the study
A number of tetanus vaccine products (monovalent and multivalent) for different animal species/groups, together with related non-adjuvanted tetanus toxoid were included in this study. These products, from four different manufacturers (coded A-D) contained a range of aluminium and non-aluminium adjuvants. The vaccines tested are shown in Table 2 . All of the vaccine products used in this study were compliant with all quality requirements for manufacturing and representative of batches found to be efficacious in field studies. In addition to the tetanus antigen, non-tetanus antigens, including other clostridial antigens that are present in some of these vaccines, were tested to determine specificity of the assay (Table 5 ).
ELISA for tetanus antigen
The capture ELISA assay was essentially performed as described previously [6] . The anti-tetanus monoclonal antibody used (NIBSC code 10/134) was produced from rat hybridoma cell lines, originally provided by Wellcome Research Laboratories (Beckenham, Kent). This antibody neutralises tetanus toxin and has been characterised previously [10] . In some assays, a reference TTxd (2nd WHO International Standard for Tetanus Toxoid for use in Flocculation Test, NIBSC code 04/150) was included which is representative of tetanus toxoid used in production of tetanus vaccine for human use. Test samples were prediluted to give a starting concentration comparable to that of a reference toxoid (in the range 0.05-0.25 Lf/ml) and titrated (using either 2-fold or 3-fold dilutions) on ELISA plates coated with the anti-tetanus monoclonal antibody (NIBSC code 10/134). The amount of antigen bound to the monoclonal antibody was visualised by successive incubations with polyclonal antibody against tetanus toxoid (NIBSC code 10/132), HRP labelled antibody, and substrate. Following colour development, optical density was measured at 405 nm on a V max microplate reader (Molecular Devices, Wokingham, UK).
Desorption study
For desorption studies, vaccine samples containing aluminium adjuvant were centrifuged at 13,000 rpm for 10 min to separate non-adsorbed antigen (contained in the supernatant) from the adsorbed antigen (contained in the pellet). The pellet was re-suspended in a solution of sodium EDTA (1 volume of 56 g/L EDTA: 49 volumes of 90 g/L disodium hydrogen phosphate) and incubated for 16-20 h at +37°C prior to titration in the assay.
Specificity
For titration of non-tetanus antigens commonly included in multicomponent tetanus vaccines for veterinary use, samples were pre-diluted 1/10. A drop-out multi-component vaccine from one manufacturer was also tested at a dilution of 1/100. This vaccine contained flu antigens but not the tetanus antigen normally included in the final vaccine formulation.
Statistical analysis
Raw data from all individual plates were analysed using a fourparameter logistic model (sigmoid curves) model, with a log transformation of the assay OD response. Analysis was performed using EDQM CombiStats Software Version 5.0 [CombiStats v5.0, EDQM-Council of Europe. www.combistats.eu]. The similarity (parallelism) of a pair of dose response curves was assessed by comparing the fitted slope factors, upper asymptotes and lower asymptotes. Variability between relative potency estimates has been expressed using geometric coefficients of variation (GCV = {10 s -1} × 100% where s is the standard deviation of the log 10 transformed estimates).
Results
Titration of non-adjuvanted TTxd (drug substance)
Non-adjuvanted TTxd from all four vaccine manufacturers was titrated in the capture ELISA. The toxoid samples titrated in a dose dependent manner, although one toxoid had a noticeably smaller dynamic range compared to the reference toxoid, toxoids from other manufacturers and a different toxoid from the same manufacturer ( Fig. 1 ). Three different toxoid batches were available from manufacturers B and D and these were titrated in three further independent assays with an expanded dilution range in order to obtain a full dose response curve. The results from a representative assay are shown in Fig. 2 .
Visual inspection of the dose response curves suggested a difference in the shape of the curve between the reference TTxd and the test samples from all 4 vaccine manufacturers. For the toxoid samples from manufacturers B and D, where 3 batches were tested in 3 independent assays, we compared the dose response curves by assessing the fitted slope factors, upper and lower asymptotes. To compare the dose response curves for each toxoid against the reference toxoid, and against the other toxoids from the same manufacturer, the difference in upper asymptotes, difference in lower asymptotes and ratio of slope factors were determined. Differences in asymptotes of < -0.05 or > 0.05 and a geometric mean slope ratio of < 0.90 or > 1.11 were highlighted as meaningful differences. The geometric mean slope ratio from 3 assays was within 0.90-1.11 for all comparisons (not shown). Similarly, the difference in lower asymptotes was within −0.05 to 0.05 for all comparisons (not shown). However, larger differences were observed in upper asymptotes particularly for the veterinary TTxds compared to the 04/150 reference toxoid (Table 1) . Differences were also observed for comparisons between some toxoid batches from the same manufacturer (manufacturer B). For comparison, TTxd used in tetanus vaccines for human use, from two different manufacturers, were also included and no differences relative to the 04/150 reference toxoid were observed for any of the parameters being assessed (not shown).
Titration of tetanus vaccine (drug product)
All of the tetanus vaccines included in the study were titrated directly in the capture ELISA with no pre-treatment to remove adjuvant. These vaccine samples contained a range of different adjuvant types, including aluminium-based and non-aluminium based adjuvants ( Table 2 ). In each case a non-adjuvanted TTxd sample, representative of the manufacturer and product being tested, was included for comparison of the dose response. All of the vaccine samples titrated in a dose dependent manner with significant regression of the dose response curve. Multiple independent assays were performed for each vaccine, and a representative dose response curve for each product type is shown in Fig. 3 (vaccines containing an aluminium adjuvant) and Fig. 4 (vaccines containing a non-aluminium adjuvant).
As described for the analysis of dose response curves for non-adjuvanted TTxd, dose response curves were compared for the final vaccine with adjuvant to the "product-type matched" non-adjuvanted TTxd sample. These results, expressed as the difference in upper asymptote and slope ratio are summarised in Table 2 . For the lower asymptote, the average difference for all products was within −0.05 to 0.05 and this data is not shown in Table 2 . For the products containing non-aluminium adjuvants, the dose response curves for the vaccine were comparable to the matched TTxd. In contrast, differences in upper asymptote or slope ratio were seen for products containing aluminium adjuvant, most notably those containing KAl(SO 4 ) 2 and AlPO 4 adjuvant where differences in the upper asymptote and/or slope ratio were observed in almost all assays. Some differences (in the slope ratio) were also seen for the products containing Al(OH) 3 adjuvant ( Table 2) .
For the purposes of obtaining a set of relative potency estimates for further evaluation, two dose response curves were considered to provide a valid estimate if differences in asymptotes were in the range −0.1 to 0.1 and the slope factor ratio was in the range 0.80-1.25. These criteria were used to exclude pairs of dose response curves showing poor parallelism in this study and should not be interpreted as suitable values for routine use in the assessment of assay validity. For each valid assay, relative potency for the vaccine samples was determined against the product-type matched non-adjuvanted toxoid. In each case, the reference toxoid was assigned an arbitrary value of 1 and the resulting potency estimates were used to calculate a between assay Geometric Coefficient of Variation (GCV). The between assay GCV ranged from 2.0% for the monovalent tetanus vaccine from Manufacturer D to 15.9% for the multivalent tetanus vaccine from Manufacturer B (Table 3 ).
Effect of desorption on dose response and antigen recovery
Vaccine samples containing aluminium adjuvant were subjected to a desorption procedure to elute the TTxd from the adjuvant. The eluted antigen was titrated in the assay to allow an estimation of antigen recovery, and to compare the effect of desorption on the comparability of the dose response curve (to non-adjuvanted TTxd). For each vaccine, Fig. 1 . Dose response curves obtained for TTxds produced by four different tetanus vaccine manufacturers. The reference toxoid 04/150 was diluted to a starting concentration of 0.069 Lf/ml. TTxd samples were pre-diluted (between 1/50,000 and 1/100) to obtain a dose response in the same range as the reference toxoid. All samples were titrated in 2-fold serial dilutions on a single ELISA plate with n = 4 replicates for 04/150 (shown as mean ± sd) and n = 1 for the test samples. Fig. 2 . Dose response curves for TTxds from Company B and D. Data shown is from 1 of 3 independent assays. The reference toxoid 04/150 was diluted to a starting concentration of 0.276 Lf/ml and TTxd samples were pre-diluted (between 1/12,500 and 1/1000) to obtain a dose response in the same range as the reference toxoid. All samples were titrated in 3-fold serial dilutions on a single ELISA plate with n = 2 replicates (shown as mean ± sd). three samples were prepared: 1) a non-adsorbed fraction (consisting of the supernatant of a centrifuged vaccine sample); 2) an adsorbed fraction (consisting of the pellet that remains after centrifugation which is re-suspended and subjected to the desorption procedure); 3) the whole vaccine. For each sample, the response for the whole vaccine was arbitrarily assigned a value of 100 and measurements of the non-adsorbed fraction and adsorbed fraction were then calculated relative to the whole vaccine. These measurements are summarised in Table 4 .
Two vaccines containing AlPO 4 adjuvant (Manufacturer D) had the lowest degree of adsorption. Based on the amount of antigen detected in the non-adsorbed and adsorbed fractions, the proportion of the tetanus antigen detected when the whole vaccine is titrated without any desorption step was close to 90% for both of these vaccine samples. The tetanus antigen in three of the vaccine samples was at or near 100% adsorption (all Manufacturer B, containing Al(OH) 3 or KAl(SO 4 ) 2 adjuvant). In these three multivalent vaccines the proportion of antigen detected when the whole vaccine was titrated was between 50 and 60%. The monovalent vaccine from manufacturer A, containing KAl (SO 4 ) 2 adjuvant, had approximately two thirds of the tetanus antigen adsorbed to the adjuvant, and the proportion of antigen detected when the whole vaccine was titrated was around 67% (Table 4) . Where we had observed differences in the upper asymptote of the dose response curve for the whole vaccine compared to the matched non-adjuvanted TTxd, we did not see any improvement for the eluted antigen vs. the matched non-adjuvanted TTxd, although the slope ratio for some of the products (most notably products 1 and 3 from Manufacturer B) was closer to 1 (data not shown).
Specificity of antigen detection
A number of non-tetanus antigens that are present in the final formulation of some multivalent tetanus vaccines for veterinary use were titrated in the ELISA to confirm specificity of antigen detection. Nontetanus antigens (including multiple antigens from other clostridia) were tested from three different veterinary vaccine manufacturers, either as individual antigen preparations representative of the antigens used in formulation of the multivalent vaccine, or in a final formulation product that had been manufactured specifically to exclude the tetanus antigen (drop-out vaccine). We did not detect any signal or dose response from any of the non-tetanus antigens or drop-out vaccine samples. A representative figure for some of the non-tetanus antigens from one manufacturer is shown in Fig. 5 and a similar pattern was seen for all of the non-tetanus (or tetanus drop-out) samples listed in Table 5 . Table 1 Summary of curve analysis performed on non-adjuvanted tetanus toxoids from Company B and D. Data are the difference in upper asymptote for toxoid samples compared to a reference toxoid (04/150) or another toxoid from the same company. Differences that are < -0.05 or > 0.05 are denoted by boxes shaded in grey.
Table 2
Summary of curve analysis for the dose response of final vaccine lots from 4 different manufacturers A-D tested in up to 7 independent assays. Data are the difference in upper asymptote and the slope ratio for the final lot vaccine samples compared to a matched non-adjuvanted TTxd. Differences in upper asymptotes that are < -0.05 or > 0.05 and slope ratios that are < 0.90 or > 1.11 are denoted by boxes shaded in grey. ND = not done.
Discussion
The amount and quality of an antigen is a major determinant for the effectiveness of a vaccine so in vitro assays that can measure these attributes are an attractive approach for development of quality control tests that can potentially replace animals for potency testing of some vaccines. Immunoassays are used routinely in the quality control of many vaccines and in some cases have been specifically developed as alternatives to in vivo potency tests [3, [11] [12] [13] [14] [15] [16] [17] [18] . Within the VAC2VAC project, our aim is to develop an immunoassay that can be used in the quality control of tetanus vaccines, and potentially substitute for the in vivo potency tests that are currently used. We previously developed an ELISA method for tetanus toxoid and showed that this is suitable for monitoring the consistency of production of tetanus vaccines based on measurement of antigen content and the degree of adsorption [6] . This, and other methods are now being explored further in the VAC2VAC project to determine whether they can serve as substitutes for existing in vivo assays. This earlier work was done exclusively with tetanus vaccines for human use but tetanus vaccines for veterinary use have significant qualitative differences to those used in humans, including purity of the antigen, adjuvant type and the presence of other non-tetanus antigens in the final formulation (including antigens that are not found in human vaccines, such as antigens from other clostridia). In the ELISA method used in this study, all of the non-adjuvanted toxoid batches produced a good dose response curve in the ELISA assay with the exception of one toxoid sample from one manufacturer. In some cases, we observed differences in the dose response curves for two toxoids produced by the same manufacturer. For all of the non-adjuvanted veterinary tetanus toxoids, the shape of the dose response curve was different when compared to a reference batch of tetanus toxoid representative of antigen used in production of tetanus vaccine for human use, which may be reflective of differences in the detoxification process used. This suggests that it may not be possible to have a common reference toxoid for calculation of relative antigen content for all tetanus toxoids. However, this is not in itself a barrier to further development of an assay and it is not uncommon for products to be controlled using a manufacturer or even product-specific reference preparation. The immunoassay was highly specific for the tetanus antigen and we did not see any signal in the ELISA for a large number of antigens, including other clostridial antigens, that are found in combination with tetanus toxoid in some vaccines for veterinary use. This extends the findings from our earlier study where we showed that the same immunoassay did not recognise any other antigens that are commonly found in combination vaccines used in humans [6] .
When final vaccine samples (containing adjuvant) were titrated directly in the ELISA, we observed good dose response curves for all samples. This was true for vaccines containing aluminium and non-aluminium adjuvants. Analysis of the differences in asymptotes and slope ratio between the whole vaccine and a matched non-adjuvanted toxoid provides some indication of the recognition of the tetanus antigen by the antibodies in the absence and in the presence of adjuvant. Compared to the dose response for the non-adjuvanted TTxd, we observed differences in the upper asymptote and/or slope ratio for vaccines containing aluminium adjuvant -particularly those containing AlPO 4 or KAl(SO 4 ) 2 adjuvant. Adsorption to aluminium adjuvant may affect stability and/or conformation of a protein antigen [19, 20] which may alter antibody binding/recognition, as could steric hindrance from the close association of antigen and adjuvant. Interestingly, for vaccines containing a non-aluminium adjuvant, the dose response curve for the non-adjuvanted toxoid was comparable to the response curve for the whole vaccine -perhaps suggesting that the adjuvant present in these vaccines does not affect antigen structure or integrity and does not interfere with epitope recognition. Multiple assays were performed for all products and the assays considered to be valid using the criteria defined above were used to calculate a potency estimate for the vaccine relative to the product-type matched non-adjuvanted tetanus toxoid. Data from between 3 and 6 independent valid assays for the vaccines tested showed that the assay can be used for quantification of tetanus antigen (in relative terms) and the between assay variation was low considering that the assay used in this study has not been optimised for any particular product type. The between assay GCV was below 10% for 5 of the 9 products and below 15% for 8/9 which is comparable to the level of variation seen for other antigen ELISA methods [11, 12, 21] .
By applying a desorption step to elute the antigen from the aluminium adjuvant, we were able to estimate the degree of adsorption of antigen in the final lot and then calculate the approximate proportion of the antigen that was detected when the vaccine was titrated directly in the ELISA assay (with an assumption that the desorption step was at or very close to being 100% efficient). The degree of adsorption for the tetanus antigen varied between the different vaccine products but was lowest for the two vaccines containing aluminium phosphate adjuvant. Adsorption of antigen to aluminium adjuvant occurs via multiple mechanisms and ligand exchange drives the strongest interaction between antigen and aluminium adjuvant [20] . Ligand exchange is stronger with aluminium hydroxide than it is with aluminium phosphate and this explains (at least in part) why the degree of adsorption varies markedly for different vaccine products containing different aluminium adjuvants. Based on a comparison of a Relative to the amount detected in the whole vaccine sample which was assigned an arbitrary value of 100. b Desorbed fraction expressed as a % of the combined value for the non-adsorbed and adsorbed fractions. c The sum of the antigen measured in the non-adsorbed and desorbed fraction as a % of the antigen measured in the whole vaccine.
Fig. 5.
Detection of non-tetanus antigens from Manufacturer B using the NIBSC capture ELISA. Dose response for a 2-fold titration of a reference toxoid (04/ 150, starting concentration 0.069 Lf/ml, pre-dilution of 10,000) and non-tetanus antigens (pre-dilution 1/10). Data is from a single assay, with n = 2 for the reference toxoid and n = 1 for the test samples.
Table 5
Non-tetanus antigens and tetanus-drop-out vaccines tested in the capture ELISA assay to determine specificity. All non-tetanus antigen samples were titrated from a pre-dilution of 1/10 with the exception of the drop-out vaccine from company C which was tested with a pre-dilution of 1/100. All of the non-tetanus antigens and tetanus drop out vaccines showed a negative response in the ELISA assay similar to that seen for selected antigens in the amount of antigen detected in the non-adsorbed and desorbed fractions (relative to what was detected in the whole vaccine), we found that the immunoassay was not able to detect all of the tetanus antigen present in the vaccine. As might be expected, the amount detected was highest (around 90%) for the two vaccines with the lowest degree of adsorption, but lower for the other vaccines with around 50% detection for the two highly adsorbed products containing aluminium hydroxide as the adjuvant. In all cases, the immunoassay does detect some of the antigen that is adsorbed to aluminium adjuvant (because the amount of non-adsorbed antigen detected in the supernatant fraction is always less than 100% relative to the amount detected in the whole vaccine) but it does not recover all of the antigen. The reasons for incomplete detection of antigen in the presence of aluminium adjuvant may be due to conformational changes in the protein following adsorption and/or steric inhibition that limit the interaction between the antibody and antigen. Such effects may be more apparent when a monoclonal antibody is used to capture the antigen (as we have done in this immunoassay) but will also depend on the antibody used and the epitope that it targets. A polyclonal antibody for antigen capture has been used in the development of an ELISA for some inactivated viral vaccines and antigen detection was not affected by the presence of aluminium adjuvant [22] . It may be the case that incomplete detection of antigen in the whole vaccine is not a barrier to development of an immunoassay with the aim of substituting for an in vivo potency test. An immunoassay that detects/recovers only a proportion of the antigen present in the vaccine may still be suitable for development as a substitute for an in vivo potency test, provided that the antigen fraction that is being detected is representative of the quality of the whole vaccine (for that antigen), and the recovered quantity is reproducible for batch to batch extraction. Other factors are clearly important here too, such as the consistency of the proportion of antigen detected over time. Other immunoassay formats, including different antibody pairs, will be explored during the VAC2VAC project. Other assay formats for antibody-based detection of vaccine antigens in the presence of adjuvant are also available, such as the DAFIA (Direct Alhydrogel Formulation Immunoassay) which has been shown to be suitable for (relative) quantification of antigen adsorbed to aluminium adjuvant [21, 23] . However, in the DAFIA method only the adsorbed fraction of the antigen is measured which, in some vaccine products, may represent < 50% of the total antigen in the vaccine. So, as with the direct titration of the whole vaccine in a capture ELISA (similar to what was done in our study), the DAFIA may only detect and quantify a proportion of the vaccine antigen. Therefore, it would also be important to demonstrate that the antigen fraction that is being detected is representative of the antigen in the whole vaccine in terms of quality. Inclusion of a desorption step increases the proportion of the vaccine antigen available for immunodetection but adds other complicating factors that require extensive investigation -for example, whether the desorption conditions affect antigen integrity and whether the desorption efficiency remains consistent amongst different batches and for vaccines of different age.
We have shown that a capture ELISA is specific and suitable for (relative) quantification of tetanus toxoid in tetanus vaccines for veterinary use. The qualitative differences in veterinary tetanus vaccines (compared to tetanus vaccine for human use) including the toxoid production process, adjuvant and vaccine formulation together with the presence of additional non-tetanus antigens, is not prohibitive to development of a quality control assay that relies on specific detection of the tetanus antigen with antibodies. It may even be the case that development of an assay for the veterinary tetanus vaccines containing non-aluminium adjuvants will be more straightforward compared to testing products containing aluminium adjuvants. This work provides a platform from which we can investigate the extent to which an immunoassay might be suitable for use as a substitute for an in vivo potency test for tetanus vaccines for veterinary use.
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